3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
81
Colorectal Neoplasms
39
Stomach Neoplasms
17
Carcinoma, Non-Small-Cell Lung
15
Liver Neoplasms
14
Neoplasms
11
Melanoma
11
Carcinoma, Renal Cell
11
Esophageal Neoplasms
10
Pancreatic Neoplasms
9
Carcinoma, Transitional Cell
8
Breast Neoplasms
8
Uterine Cervical Neoplasms
7
Triple Negative Breast Neoplasms
7
Squamous Cell Carcinoma of Head and Neck
7
Small Cell Lung Carcinoma
7
Ovarian Neoplasms
7
Head and Neck Neoplasms
7
Cholangiocarcinoma
7
Rectal Neoplasms
6
Neoplasm Metastasis
6
Colonic Neoplasms
6
Urinary Bladder Neoplasms
5
Gastrointestinal Neoplasms
5
Carcinoma, Merkel Cell
5
Biliary Tract Neoplasms
5
Prostatic Neoplasms
4
Sarcoma
3
Lung Neoplasms
3
Gallbladder Neoplasms
3
Interventions
trifluridine tipiracil drug combination
1
reolysin
1
atezolizumab
1
Gemcitabine
1
Albumin-Bound Paclitaxel
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Anal Cancer Metastatic
×
atezolizumab
×
Gastrointestinal
×
Clear all
NCT07280377
2026-05-19
GOBLET
Oncolytics Biotech
Phase 1/2
Active not recruiting
122 enrolled